Healthy Living: Restoring diabetic pancreas
UC researcher discusses possible benefits of Ginkgo biloba
An article in the magazine Healthy Living discusses the latest research from Helal Fouad Hetta, PhD, a postdoctoral fellow and scientist in the UC Division of Digestive Diseases. Ginkgo biloba, a popular dietary supplement, may offer some therapeutic benefits in fighting Type 2 diabetes, according to Hetta. He is part of a team of more than a dozen international scientists who published a study on the effects of Ginkgo biloba in rats in the journal Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.
Helal Hetta, PhD
Hetta is also on faculty at Egypt’s Assiut University College of Medicine in the Department of Medical Microbiology and Immunology.
Hetta was also featured discussing his research on Cincinnati's WVXU radio station.
Related Stories
Recent advances may speed time to endometriosis diagnosis
March 16, 2026
The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.